NewLink Genetics Corp. (NASDAQ:NLNK) Given Average Recommendation of “Hold” by Brokerages
Shares of NewLink Genetics Corp. (NASDAQ:NLNK) have received a consensus recommendation of “Hold” from the eight ratings firms that are covering the firm. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.40.
Separately, Zacks Investment Research downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th.
Several hedge funds have recently modified their holdings of the company. American International Group Inc. boosted its stake in shares of NewLink Genetics Corp. by 1.4% in the second quarter. American International Group Inc. now owns 12,455 shares of the company’s stock worth $140,000 after buying an additional 174 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of NewLink Genetics Corp. by 5.8% in the second quarter. Nationwide Fund Advisors now owns 14,160 shares of the company’s stock worth $159,000 after buying an additional 770 shares during the last quarter. SECOR Capital Advisors LP purchased a new stake in shares of NewLink Genetics Corp. during the second quarter worth $224,000. Coe Capital Management LLC purchased a new stake in shares of NewLink Genetics Corp. during the second quarter worth $225,000. Finally, State Board of Administration of Florida Retirement System boosted its stake in shares of NewLink Genetics Corp. by 5.8% in the second quarter. State Board of Administration of Florida Retirement System now owns 21,334 shares of the company’s stock worth $240,000 after buying an additional 1,164 shares during the last quarter. Institutional investors and hedge funds own 50.10% of the company’s stock.
Shares of NewLink Genetics Corp. (NASDAQ:NLNK) traded down 7.12% on Thursday, reaching $14.61. 362,405 shares of the company’s stock traded hands. The company’s 50-day moving average is $11.44 and its 200-day moving average is $12.76. The firm’s market capitalization is $423.24 million. NewLink Genetics Corp. has a 52 week low of $9.23 and a 52 week high of $46.34.
NewLink Genetics Corp. (NASDAQ:NLNK) last announced its quarterly earnings data on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.35. NewLink Genetics Corp. had a negative net margin of 316.38% and a negative return on equity of 51.33%. Equities research analysts anticipate that NewLink Genetics Corp. will post ($3.06) earnings per share for the current fiscal year.
NewLink Genetics Corp. Company Profile
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.
Receive News & Stock Ratings for NewLink Genetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp. and related stocks with our FREE daily email newsletter.